-
Product Insights
NewNet Present Value Model: I-Mab’s Uliledlimab
Empower your strategies with our Net Present Value Model: I-Mab's Uliledlimab report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – TRV-045 in Epilepsy
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - TRV-045 in Epilepsy report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. TRV-045 in Epilepsy Drug Details: TRV-045 is under development for the treatment of...
-
Product Insights
NewOpium Withdrawal Syndrome – Drugs In Development, 2024
Empower your strategies with our Opium Withdrawal Syndrome – Drugs In Development, 2024 report and make more profitable business decisions. Opioid withdrawal syndrome is a life-threatening condition resulting from opioid dependence. Opioid withdrawal is a set of symptoms arising from the sudden withdrawal or reduction of opioids where previous usage has been heavy and prolonged. Signs and symptoms of withdrawal can include drug craving, anxiety, restless legs, nausea, vomiting, diarrhea, sweating, and an increased heart rate. The Opium Withdrawal Syndrome drugs...
-
Product Insights
NewChemotherapy Induced Peripheral Neuropathy – Drugs In Development, 2024
Empower your strategies with our Chemotherapy Induced Peripheral Neuropathy – Drugs In Development, 2024 report and make more profitable business decisions. Chemotherapy-induced peripheral neuropathy (CIPN) is a side effect of cancer treatment. Symptoms include pain, burning, tingling, constipation, muscle weakness, blood pressure changes, and balance problems. Risk factors include longer duration of therapy, pre-existing neuropathy, and type of chemotherapeutic agent. The Chemotherapy Induced Peripheral Neuropathy drugs in development market research report provide comprehensive information on the therapeutics under development for Chemotherapy...
-
Product Insights
NewOpium (Opioid) Addiction – Drugs In Development, 2024
Empower your strategies with our Opium (Opioid) Addiction – Drugs In Development, 2024 report and make more profitable business decisions. Opioid addiction develops after using opioids regularly for a period of time. Prolonged use of opiates can lead to nerve damage within the brain that causes cells to stop producing endogenous opiates (natural painkillers, known as endorphins). This can lead to an inability of the body to stop pain, because there are no endorphins to mask the pain initially. The degeneration...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – PB-1002 in Solid Tumor
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. PB-1002 in Solid Tumor Drug Details: PB-1002 is under development for the treatment of hormone...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – MK-1092 in Type 1 Diabetes (Juvenile Diabetes)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - MK-1092 in Type 1 Diabetes (Juvenile Diabetes) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. MK-1092 in Type 1 Diabetes (Juvenile Diabetes) Drug...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Gene Therapy to Activate LAMB-3 for Junctional Epidermolysis Bullosa in Epidermolysis Bullosa
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Gene Therapy to Activate LAMB-3 for Junctional Epidermolysis Bullosa in Epidermolysis Bullosa report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.Gene Therapy To Activate Lamb-3...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – TQB-2858 in Hematological Tumor
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. TQB-2858 in Hematological Tumor Drug Details: TQB-2858 is under development for the treatment of advanced...